Zimmer Biomet commenced limited U.S. launch of Signature Solutions™, clinical services and technologies to assist hospitals and medical practices with the transition to value-based healthcare models.
Pre-clinical studies suggest that multipotent adult progenitor cells (MAPCs), such as the technology used in RTI Surgical’s map3® Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. mesenchymal stem cells in vitro.
MiMedx is planning a U.S. launch for a next-generation lyophilized version of OrthoFlo, its amniotic fluid-based allograft for use in in orthopaedic and sports-medicine applications. Â
Study results suggest that AMNIOX Medical’s CLARIX®  FLO and CLARIX® CORD 1K regenerative therapies improved outcomes in plantar fasciitis treatment and tarsal coalition repair.
Since mid-May, both Medtronic and Zimmer Biomet have announced strategic moves in the 2-level cervical disc replacement and robotic surgery markets. In efforts to invigorate revenue growth, the two have focused on niche technologies that should expand their portfolios-but have yet to prove wide scale.
Stryker Performance Solutions launched Episode Performance Manager™, a digital tool to translate raw claims data provided by Medicare into dynamic reports to compare performance of hospitals participating in the Comprehensive Care for Joint Replacement initiative.
Medtronic received FDA 510(k) clearance to market the CD Horizon® Fenestrated Screw Set, indicated for treatment of advanced stage tumors in the thoracic and lumbar spine.